Peptide

Zhenoluten

Also known as

A-15 · A-15 ovary bioregulator · ovary cytomax · Jenoluten · Khavinson ovary complex · Zhenoluten peptide

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Ovarian-tissue peptide mixture	Zhenoluten, also spelled Jenoluten, is the oral Cytomax A-15 animal-tissue mixture discussed for cycle changes, perimenopause and fertility preparation.
Ovarian-support claim	It is neither estrogen nor progesterone, and Ovagen is a different liver-oriented product. Tissue-specific signaling claims do not establish restoration of egg supply.

Notes

Zhenoluten is an oral ovarian-tissue peptide mixture discussed for cycle changes, perimenopause and fertility preparation. Accounts include hormone changes, temporary follicle increases, unchanged outcomes and cysts. Most involve other treatment, so there is no dependable promise of benefit.

A-15 is an oral animal-tissue peptide mixture. Zhenoluten, also spelled Jenoluten, is the ovary-targeted Cytomax product. It is neither estrogen nor progesterone; Ovagen is a different liver-oriented peptide.

The appeal is supporting ovarian function. People discuss it for irregular cycles, perimenopause and fertility preparation. The idea of tissue-specific signaling does not establish that capsules restore egg supply. Independent educational review of Zhenoluten (Community opinion · Accessed 2026-09-30)

Source context — Independent educational review of Zhenoluten: Secondary author opinion with supplier navigation; not a primary study or first-person use. Its claim that the manufacturer report has no methods/control arm is contradicted by the inspected PDF. Blanket claims of no human hormone/cycle measurements are qualified, not copied.

What people notice

Hormone tests	One user reported FSH, an ovarian-signaling hormone, halving after three weeks and other elevated hormones normalizing. The account does not isolate a Zhenoluten effect or demonstrate better egg quality.
Temporary or absent follicle changes	One user's initially unchanged follicle count later rose by five, then returned to baseline. Other treatments had produced similar changes in that person's history.
Fertility histories are mixed	Conception reports coexist with limited response during fertility care and cysts or missed periods. Multiple products and treatments prevent assigning those outcomes to Zhenoluten alone.

Notes

Cycle and fertility changes matter more than an acute feeling. Forum users track hormone tests, ultrasound follicle counts and conception. These are different outcomes: a lower test result or more visible follicles does not by itself demonstrate better egg quality or a pregnancy benefit. Patient's fertility, cyst and menstrual-change timeline (Personal report · Accessed 2026-09-30)

A hormone-test change in one account. Olivia reported FSH, a hormone linked to ovarian signaling, halving after three weeks and other elevated hormones normalizing. This does not isolate a Zhenoluten effect. Peptides: who took Zhenoluten and Endoluten? (Community discussion · Accessed 2026-09-30)

Five additional follicles, then a return to baseline. Vera's count rose after a month of a repeat course, then declined. She gave no precise persistence interval. This is outcome history, not single-dose duration. Peptides: who took Zhenoluten and Endoluten? (Community discussion · Accessed 2026-09-30)

Stronger nails, but initially no follicle change. Vera described stronger nails without an initial follicle-count change. Her later increase disappeared, and she said other therapies had produced similar results. The full timeline therefore leaves attribution uncertain. Peptides: who took Zhenoluten and Endoluten? (Community discussion · Accessed 2026-09-30)

One-week pregnancy is not an onset measurement. Strawberry conceived a week after starting Zhenoluten plus Endoluten, preventing planned laboratory follow-up. That cannot establish either product's time to act. Glandokort and Zhenoluten: who took them? (Community discussion · Accessed 2026-09-30)

Limited response during fertility care. A September 2026 user taking Zhenoluten and Endoluten reported one egg retrieved and preparation for another retrieval, with low ovarian reserve. Glandokort and Zhenoluten: who took them? (Community discussion · Accessed 2026-09-30)

One patient's hopeful and adverse experiences belong together. Leisan reported conception after a month with Zhenoluten and prenatal vitamins, and a later pregnancy during several interventions that ended in loss, which she attributed to COVID. After Zhenoluten plus Endoluten in 2022, she reported two cysts and three months without periods; these resolved following treatment. A further peptide course coincided with renewed delays, then hormone treatment brought her period back. She was still seeking fertility help. This is one complicated history, not several independent successes or proof of causation. Patient's fertility, cyst and menstrual-change timeline (Personal report · Accessed 2026-09-30)

Cysts and menstrual disruption are reported. Yulyasha described cysts after Endoluten, Zhenoluten and Ovariamin, requiring three weeks of Norkolut treatment. Another patient's timeline includes cysts and absent periods. Neither account proves which product caused them. Glandokort and Zhenoluten: who took them? (Community discussion · Accessed 2026-09-30) · Patient's fertility, cyst and menstrual-change timeline (Personal report · Accessed 2026-09-30)

Source context — Patient's fertility, cyst and menstrual-change timeline: Patient-created report on medical Q&A platform, not controlled evidence; pregnancy loss cause is her attribution. Unnamed replies contain a procedure terminology error and are not relied on. Multiple products, vitamins, device, infection and hormone treatment confound all outcomes.

Source context — Peptides: who took Zhenoluten and Endoluten?: Translated self-reports; Vera's two replies are ONE account. Dose absent for Vera and Olivia; other treatments and natural changes complicate attribution.

Source context — Glandokort and Zhenoluten: who took them?: Fertility-care setting, translated unverified accounts, no isolated dose/outcome test. Strawberry's conception has no follow-up lab trend. Yulyasha may be the same commenter in inaccessible 2024 thread: do not count as independent corroboration.

Doses people talk about

Forum capsule counts	Separate oral regimens describe two capsules daily or two capsules twice daily, often with Endoluten. Capsule strength was not restated, so those counts cannot automatically become milligrams.
Labeled-complex charts	Old charts declare 10 mg per capsule and list one daily, one twice daily or two twice daily: 10, 20 or 40 mg/day of labeled complex. These are conventions, not validated doses.
Food timing	With meals, 5–10 minutes before meals and preferably mornings all appear in charts, without comparative outcomes.

Notes

Forum amounts: 2 capsules daily or 2 capsules twice daily. The preserved fertility-forum record describes these as separate oral regimens, commonly with Endoluten. The latter totals four capsules/day. Those posters did not restate capsule strength; do not automatically convert their capsule counts to milligrams.

Charts declare 10 mg per capsule. Old charts list 1–2 capsules, 1–2 times/day. Variants of 1 daily, 1 twice/day or 2 twice/day correspond to 10, 20 or 40 mg/day of labeled complex. These are conventions, not validated doses.

Food timing varies. Charts say with meals, 5–10 minutes before or preferably mornings, without comparative outcomes.

Half-life, onset & duration

Felt onset	Immediate feel is unknown. One hormone-test change was reported after three weeks; conception a week after starting Zhenoluten plus Endoluten is not an onset measurement.
Felt duration	Single-dose and after-stopping benefit windows are not established. One follicle-count increase later returned to baseline without a precise persistence interval.
Half-life	No dependable human half-life is established for the A-15 mixture. Capsule frequency, course length and later hormone tests do not measure clearance.

Notes

Three weeks in one hormone account; immediate feel unknown. Olivia's test change was reported after three weeks, rather than a reproducible sensation after one capsule. Peptides: who took Zhenoluten and Endoluten? (Community discussion · Accessed 2026-09-30)

Long courses do not prove lasting benefit. A reported month or several months of capsule use describes exposure. The inspected community accounts do not establish a dependable benefit window after stopping.

No dependable human half-life number. The community record does not establish how quickly the A-15 mixture leaves the body. Capsule frequency, a month-long course and later hormone changes cannot supply that measurement.

Cycles people discuss

Personal month-long courses	One user described a month, then a two-month repeat three months later. A September 2026 poster was finishing month three, with results still pending.
Competing calendars	Charts include 10–30 days once or twice yearly, or 30 days followed by 10-day packs every 1–3 months. A four-intensive-courses-per-year Reddit post was a plan, not a completed result.

Notes

One month, then a two-month repeat three months later. Vera described an initial one-month course and, three months later, a two-month repeat. Separate replies mention three-month treatment and a seller's suggestion of four months; those are different histories and proposals. Peptides: who took Zhenoluten and Endoluten? (Community discussion · Accessed 2026-09-30)

Three months in a September 2026 account. Ryzhulya was finishing month three, with two months of Endoluten and laboratory results still pending. Glandokort and Zhenoluten: who took them? (Community discussion · Accessed 2026-09-30)

Calendars differ. Charts give 10–30 days once or twice/year, or 30 days then 10-day packs every 1–3 months; other repeat intervals are 3–6 months. A Reddit plan for four intensive courses/year was an intention.

Four intensive courses were a costly plan. One Reddit poster planned four intensive courses in a year and raised cost concerns. That is a proposed experiment; the requests for updates did not supply a completed outcome.

Stacks

Endoluten	Endoluten accompanies several fertility accounts. One cyst report involved Endoluten, Zhenoluten and Ovariamin together, so the responsible ingredient is unknown.
Other fertility or hormone layers	Prenatal vitamins and other fertility interventions appear in a patient's history. A supplier FAQ pairs A-15 with Thyreogen and Ventfort; its no-side-effects assurance is not evidence.

Notes

Stacks complicate credit. Endoluten appears in several accounts. A supplier FAQ repeated on Rapamycin News pairs A-15 with Thyreogen and Ventfort; its no-side-effects assurance is not evidence. Bioregulator FAQ circulated on Rapamycin News (Secondhand community claim · Accessed 2026-09-30)

Source context — Bioregulator FAQ circulated on Rapamycin News: Copied supplier material linked to Qi/IAS; not personal Zhenoluten use. Origin family overlaps commercial Cytomax copy. Unrelated BPC, MOTS-C and SS-31 experiences excluded.

Watch for

Cysts and menstrual disruption	Accounts include cysts and missed periods during multi-product courses, followed by treatment. Which product caused them is unknown.
Pregnancy and intolerance	Pregnancy and breastfeeding are listed cautions. Fertility-preparation use does not establish pregnancy safety; animal-derived contents and capsule ingredients matter for allergies and digestive intolerance.
Hormone-sensitive conditions	The record flags endometriosis, estrogen-sensitive disease, pelvic pain and unusual bleeding. Capsule experiments cannot replace gynecologic or fertility evaluation, and long-term interaction safety is uncertain.

Notes

Pregnancy, breastfeeding and intolerance are listed cautions. Fertility-preparation talk does not establish pregnancy safety. Animal-derived contents and capsule ingredients matter for allergies; the old record also flags possible digestive intolerance without a measured rate.

Hormone-sensitive conditions and unusual bleeding need care. The existing discussion flags endometriosis or estrogen-sensitive disease, pelvic pain and bleeding changes. Capsule experiments cannot replace gynecologic evaluation, hormone treatment or fertility workups. Patient's fertility, cyst and menstrual-change timeline (Personal report · Accessed 2026-09-30)

Interactions and long-term use remain uncertain. Concurrent hormones, supplements and bioregulators obscure attribution. No interaction-free or indefinite-use assurance follows from these accounts. Capsule storage notes describe dry, dark conditions at 2–25 °C.

Full notes

What Zhenoluten is

A-15 is an oral animal-tissue peptide mixture. Zhenoluten, also spelled Jenoluten, is the ovary-targeted Cytomax product. It is neither estrogen nor progesterone; Ovagen is a different liver-oriented peptide. Community
The appeal is supporting ovarian function. People discuss it for irregular cycles, perimenopause and fertility preparation. The idea of tissue-specific signaling does not establish that capsules restore egg supply. Community Bioregulator Peptides

What people hope for and notice

Cycle and fertility changes matter more than an acute feeling. Forum users track hormone tests, ultrasound follicle counts and conception. These are different outcomes: a lower test result or more visible follicles does not by itself demonstrate better egg quality or a pregnancy benefit. Personal report Community
A hormone-test change in one account. Olivia reported FSH, a hormone linked to ovarian signaling, halving after three weeks and other elevated hormones normalizing. This does not isolate a Zhenoluten effect. Babyblog
Menopause comfort remains a claim to evaluate. Hot flashes and cycle regularity are prominent promotional goals. The independent reviewer is skeptical about spending money expecting measurable improvement; that opinion is distinct from an actual no-benefit user diary. Community Bioregulator Peptides

Doses people discuss

Reported use and circulated charts are discussion, not a personal regimen.

Forum amounts: 2 capsules daily or 2 capsules twice daily. The preserved fertility-forum record describes these as separate oral regimens, commonly with Endoluten. The latter totals four capsules/day. Those posters did not restate capsule strength; do not automatically convert their capsule counts to milligrams. Community
Charts declare 10 mg per capsule. Old charts list 1–2 capsules, 1–2 times/day. Variants of 1 daily, 1 twice/day or 2 twice/day correspond to 10, 20 or 40 mg/day of labeled complex. These are conventions, not validated doses. Community
Food timing varies. Charts say with meals, 5–10 minutes before or preferably mornings, without comparative outcomes. Community

Half-life

No dependable human half-life number. The community record does not establish how quickly the A-15 mixture leaves the body. Capsule frequency, a month-long course and later hormone changes cannot supply that measurement. Community

Onset: when a change appears

Three weeks in one hormone account; immediate feel unknown. Olivia's test change was reported after three weeks, rather than a reproducible sensation after one capsule. Babyblog Community
One-week pregnancy is not an onset measurement. Strawberry conceived a week after starting Zhenoluten plus Endoluten, preventing planned laboratory follow-up. That cannot establish either product's time to act. Babyblog

Duration: how long changes last

Five additional follicles, then a return to baseline. Vera's count rose after a month of a repeat course, then declined. She gave no precise persistence interval. This is outcome history, not single-dose duration. Babyblog
Long courses do not prove lasting benefit. A reported month or several months of capsule use describes exposure. The inspected community accounts do not establish a dependable benefit window after stopping. Community

Courses and time off

One month, then a two-month repeat three months later. Vera described an initial one-month course and, three months later, a two-month repeat. Separate replies mention three-month treatment and a seller's suggestion of four months; those are different histories and proposals. Babyblog
Three months in a September 2026 account. Ryzhulya was finishing month three, with two months of Endoluten and laboratory results still pending. Babyblog
Calendars differ. Charts give 10–30 days once or twice/year, or 30 days then 10-day packs every 1–3 months; other repeat intervals are 3–6 months. A Reddit plan for four intensive courses/year was an intention. Community

Good to know

Cysts and menstrual disruption are reported. Yulyasha described cysts after Endoluten, Zhenoluten and Ovariamin, requiring three weeks of Norkolut treatment. Another patient's timeline includes cysts and absent periods. Neither account proves which product caused them. Babyblog Personal report
Pregnancy, breastfeeding and intolerance are listed cautions. Fertility-preparation talk does not establish pregnancy safety. Animal-derived contents and capsule ingredients matter for allergies; the old record also flags possible digestive intolerance without a measured rate. Community
Hormone-sensitive conditions and unusual bleeding need care. The existing discussion flags endometriosis or estrogen-sensitive disease, pelvic pain and bleeding changes. Capsule experiments cannot replace gynecologic evaluation, hormone treatment or fertility workups. Community Personal report
Interactions and long-term use remain uncertain. Concurrent hormones, supplements and bioregulators obscure attribution. No interaction-free or indefinite-use assurance follows from these accounts. Capsule storage notes describe dry, dark conditions at 2–25 °C. Community

What the actual accounts add

Stronger nails, but initially no follicle change. Vera described stronger nails without an initial follicle-count change. Her later increase disappeared, and she said other therapies had produced similar results. The full timeline therefore leaves attribution uncertain. Babyblog
A brief favorable reply leaves the actual benefit unclear. Inga initially questioned using a costly supplement instead of previous cycle treatment. She later confirmed taking it and gave a vague, mildly favorable assessment, with no particular symptom, amount or measured result. Mom.life
Limited response during fertility care. A September 2026 user taking Zhenoluten and Endoluten reported one egg retrieved and preparation for another retrieval, with low ovarian reserve. Babyblog
One patient's hopeful and adverse experiences belong together. Leisan reported conception after a month with Zhenoluten and prenatal vitamins, and a later pregnancy during several interventions that ended in loss, which she attributed to COVID. After Zhenoluten plus Endoluten in 2022, she reported two cysts and three months without periods; these resolved following treatment. A further peptide course coincided with renewed delays, then hormone treatment brought her period back. She was still seeking fertility help. This is one complicated history, not several independent successes or proof of causation. Personal report
Stacks complicate credit. Endoluten appears in several accounts. A supplier FAQ repeated on Rapamycin News pairs A-15 with Thyreogen and Ventfort; its no-side-effects assurance is not evidence. Rapamycin News Community
Four intensive courses were a costly plan. One Reddit poster planned four intensive courses in a year and raised cost concerns. That is a proposed experiment; the requests for updates did not supply a completed outcome. Community Community

What the originating report actually says

A 2011 report describes a conventional-care comparison. It includes 67 women and an add-on of one 10 mg capsule twice daily for 30 days. Hormone and symptom improvements are reported, but this originating-group document is not independent confirmation or community dosing evidence. Official context